Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an ...

After weeks of sulking on the sidelines, foreign institutional investors (FIIs) have stormed back into Dalal Street with a vengeance by pumping nearly Rs 15,000 crore into Indian stocks over just the ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Eli Lilly’s weight loss pill orforglipron succeeded in a Phase 3 clinical trial in diabetes, helping study participants control their blood sugar while hinting at weight loss that might be comparable ...

Emerge is the third Phase 3 study of MM120 ODT, with the Voyage and Panorama studies in GAD already underway. “In our Phase 2b study, MADRS score improvements after a single MM120 100 µg dose ...

Emerge is the third Phase 3 study of MM120 ODT, with the Voyage and Panorama studies in GAD already underway. “In our Phase 2b study, MADRS score improvements after a single MM120 100 µg dose were ...

PRINCETON, N.J., April 14, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients ...

Ironwood Pharmaceuticals shares sank after the company said it needs to conduct a confirmatory phase 3 trial of proposed short-bowel treatment apraglutide. The stock hit a 52-week low in mid ...

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Camzyos--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month.

Please provide your email address to receive an email when new articles are posted on . Sotyktu significantly improved skin and joint symptoms of psoriatic arthritis and reduced patient-reported ...